If you are an Ochsner provider and need assistance with this site please email
[email protected]
.
ScholarlyWork@Ochsner
Toggle navigation
Browse
Home
People
Organizations
Research Areas
Publications
Capability Map
Drugs
Journal
Overview
Identity
View All
Overview
Publication venue for
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection (Oct, 10.1007/s40265-022-01797-x, 2022)
2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
2022
Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy in COVID-19"
2020
Management of Thrombotic Complications in COVID-19: An Update
2020
Pharmaco-Immunomodulatory Therapy in COVID-19
. 80:1267-1292.
2020
Identity
International Standard Serial Number (ISSN)
0012-6667
